Year-to-date revenue growth, gross margin expansion and operating expense reduction are testament to continued execution against financial objectives Planned merger with SomaLogic activates strategic M&A thesis SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2023 (GLOBE NEWSWIRE) -- BioTools Inc.
SOUTH SAN FRANCISCO, Calif. , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm , PhD, will give a presentation
SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023,
Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial
Continued operational execution improves revenue growth, margin expansion, and expense reduction SOUTH SAN FRANCISCO, Calif. , Aug. 08, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) (“Standard BioTools”, or the “Company”), driven by a bold purpose – Unleashing tools to accelerate
SOUTH SAN FRANCISCO, Calif. , July 26, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor conferences: Canaccord
SOUTH SAN FRANCISCO, Calif. , July 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2023 financial results on Tuesday, August 8, 2023, after
SOUTH SAN FRANCISCO, Calif. , June 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor conferences: Capital One
SOUTH SAN FRANCISCO, Calif. , May 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm , PhD, will give a presentation at
Supporting discovery through screening, the X9 is the only system integrating real-time PCR and NGS library preparation SOUTH SAN FRANCISCO, Calif. , May 18, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in
